Follow the conference on X #IVTherapy
This conference focuses on improving practice and patient safety to reduce Infiltration and Extravasation Injury through prevention, early recognition and treatment. Through national updates and case studies the conference will support you to understand the risk of extravasation and how to prevent, recognise, treat and escalate extravasation injuries when they do occur. Chaired by Andrew Barton Nurse Consultant IV therapy & Vascular access NIVAS Chair, the conference will open with an update on implementing and ensuring adherence to the February 2024 Infiltration and Extravasation toolkit to improve practice.
"The advantages of intravenous therapy include improved patient outcomes and survival due to constant drug bioavailability and consistent therapeutic drug levels in the blood. Unfortunately, the use of intravenous therapies is not without risk. While the benefits of using intravenous therapy usually outweighs such risks, it is necessary for all staff involved with such therapies to have sound knowledge of potential complications. ..Occasionally the administration of IV therapies can go wrong. Infiltration and Extravasation is a complication whereby the drug or IV therapy leaks into the tissues surrounding the vascular access device. Extravasation is often associated with chemotherapy agents; however nonchemotherapy drugs have been reported as having a greater risk of serious complications. Extravasation may cause serious and often life changing injuries. This tool kit is designed to highlight the risks of infiltration and extravasation and facilitate healthcare organisations to implement best practice to improve patient safety and experience.”
Andrew Barton Nurse Consultant IV therapy & Vascular access NIVAS Chair, Infiltration and Extravasation A toolkit to improve practice February 2024
“Infiltration is the inadvertent and Extravasation leakage of intravenous fluid Introduction or medication into extravascular tissue from an intravenous vascular access device, such as a peripheral cannula or central venous catheter. The resulting injury is likely to be minor. If the fluid or medication is a vesicant, the injury would be classed as an extravasation as the risk of tissue damage and serious injury is high.”
Infiltration and Extravasation A toolkit to improve practice February 2024
“From 1 April 2011 until 31 March 2021 NHS Resolution received 444 claims relating to extravasation injuries. Of those 444 claims, 138 remain open, 197 have settled with damages paid and 109 have closed with nil damages. This has cost the National Health Service (NHS) 15.6 million pounds. This includes payment for claimant legal costs, NHS legal costs and damages.”
NHS Resolution Infiltration and Extravasation A toolkit to improve practice February 2024
This conference will enable you to:
Network with colleagues who are working to reduce Extravasation Injury
Learn from outstanding practice in recognizing, treating and escalating extravasation injury
Reflect on national developments and learning
Implement and ensure adherence to the 2024 Infiltration and Extravasation toolkit to improve practice
Develop your skills in prevention, early recognition and treatment
Ensure vesicants are administered in the safest way
Develop your skills in training frontline staff to recognize evolving injuries
Understand how you can implement preventative measures
Identify key strategies for improvement
Educate patients to raise alarm and improve consent procedures
Develop protocols to support practice
Understand the role and competencies of the NHS trust lead for extravasation
Ensure effective treatment, and early intervention in severe wounds
Learn from case studies in cancer, maternity, radiology and paediatrics
Ensure you are up to date with the latest legal cases
Self assess and reflect on your own practice
Supports CPD professional development and acts as revalidation evidence. This course provides 5 Hrs training for CPD subject to peer group approval for revalidation purposes
